TGFB1 and cirrhosis of liver: Thus, as downstream transcription factors of TGF-β signaling, SMADs proteins could be the potential targets for therapeutic preventing and treatment of liver fibrosis as well as advanced liver diseases such as liver cirrhosis and HCC (3, 4).